Haematologica
(Sep 2017)
Low-dose methotrexate in myeloproliferative neoplasm models
- Kavitha Chinnaiya,
- Michelle A. Lawson,
- Sally Thomas,
- Marie-Therese Haider,
- Jenny Down,
- Andrew D. Chantry,
- David Hughes,
- Antony Green,
- Jon R. Sayers,
- John A. Snowden,
- Martin P. Zeidler
Affiliations
- Kavitha Chinnaiya
- The Bateson Centre, Department of Biomedical Science, The University of Sheffield, UK
- Michelle A. Lawson
- Department of Oncology & Metabolism, The University of Sheffield, UK
- Sally Thomas
- The Bateson Centre, Department of Biomedical Science, The University of Sheffield, UK
- Marie-Therese Haider
- Department of Oncology & Metabolism, The University of Sheffield, UK
- Jenny Down
- Department of Oncology & Metabolism, The University of Sheffield, UK
- Andrew D. Chantry
- Department of Oncology & Metabolism, The University of Sheffield, UK
- David Hughes
- Department of Histopathology, Sheffield Teaching Hospitals NHS Foundation Trust, UK
- Antony Green
- Cambridge Stem Cell Institute, Cambridge institute for Medical Research and Department of Haematology, University of Cambridge, UK
- Jon R. Sayers
- Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, UK
- John A. Snowden
- Department of Oncology & Metabolism, The University of Sheffield, UK;Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, UK
- Martin P. Zeidler
- The Bateson Centre, Department of Biomedical Science, The University of Sheffield, UK
- DOI
-
https://doi.org/10.3324/haematol.2017.165738
- Journal volume & issue
-
Vol. 102,
no. 9
WeChat QR code